Baroda BNP Paribas Value Fund
The scheme seeks to generate long-term capital appreciation from a diversified portfolio of predominantly equity and equity related instruments by following a value investment strategy.
Growthvine rating: 1/5 — ranked #21 of 23 in category.
Fund basics
| Category | Equity: Value |
|---|
| NAV | ₹13.82 (as of 2026-08-21) |
|---|
| AUM | ₹1,014 Cr |
|---|
| Expense ratio | 1.90% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ankeet Pandya |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 1 year |
|---|
Performance & risk
| Sharpe ratio | 0.25 |
|---|
| Standard deviation | 15.19% |
|---|
| Max drawdown | -20.14% |
|---|
| Alpha | -2.59 |
|---|
| Beta | 0.97 |
|---|
Over 5 years, captured 91.3% of Nifty 500's upside and 102.6% of its downside.
Market cap allocation
| Large cap | 69.2% |
|---|
| Mid cap | 20.5% |
|---|
| Small cap | 10.4% |
|---|
Concentration
| Top 5 holdings | 26.1% |
|---|
| Top 10 holdings | 41.4% |
|---|
| Total holdings | 49 |
|---|
| Index overlap | 37.1% |
|---|
| Active share | 62.9% |
|---|
Top holdings
- Reliance Industries Ltd — 6.8%
- HDFC Bank Ltd. — 5.2%
- ICICI Bank Ltd. — 5.1%
- Bharat Heavy Electricals Ltd. — 4.7%
- GE Vernova T&D India Limited — 4.3%
- Larsen & Toubro Limited — 4.0%
- Divis Laboratories Ltd. — 3.6%
- Sun Pharmaceutical Industries Ltd. — 2.7%
- Torrent Pharmaceuticals Ltd. — 2.5%
- Infosys Ltd — 2.5%
Top sectors
- Banking & Financial — 19.5%
- Pharma & Biotech — 13.0%
- Software & Services — 8.8%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | -2.8% | Q3 | #17 of 23 |
| 2025 | 1.8% | Q4 (Bottom) | #19 of 22 |
| 2024 | 14.8% | Q4 (Bottom) | #19 of 21 |